Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $26.61, moving +1.88% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.58%. On ...

Viking Therapeutics has key trial catalysts ahead and trades near biotech deal valuations, despite dilution risks. Find out ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising ...

Viking Therapeutics exceeded analyst forecasts for Q2 2024, reporting earnings per share (EPS) of -$0.20, an earnings beat compared to the consensus estimate of -$0.26.

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. I'm talking about the weight loss drug market -- one that Morgan Stanley analysts say may multiply ...

Could 2024 be a breakout year for Viking Therapeutics (NASDAQ: VKTX)? The mid-cap biotech has generated more positive headlines than most of its peers. Excitement is through the roof. Due to ...

Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront ...

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.